soul trial oral semaglutide cardiovascular outcomes (Semaglutide triaL) in individuals with SOUL Trial (NEJM 2025): Oral

Selenium cysteine (Sec) is the catalytic activity neutral of GPX, and its activity is closely related to the level of selenium content in the body

If you miss a dose and it has been less than 3 days, take the missed dose as soon as possible

A comprehensive and integrative approach for perimenopausal women involves addressing multiple facets of health to effectively manage symptoms and enhance overall well-being

These findings suggest semaglutide may offer protective effects rather than pose direct cardiac risk for many patients with heart conditions

**Neurological Disorders:** Supportive treatment in certain neurological disorders associated with vitamin B12 deficiency, such as peripheral neuropathy

Primary Target Tissue MOTS-c: The entire metabolic system, with a heavy emphasis on skeletal muscle tissue and systemic insulin regulation